'Case of the Month' from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99mTc‐sestamibi SPECT‐CT to differentiate renal cell carcinoma from benign oncocytoma.

A SP 99m sp Tc-sestamibi SPECT-CT demonstrating avid uptake therefore indicates a renal mass that could be considered as at best oncocytoma, and at worst an indolent form of RCC, which may also benefit from active monitoring, especially when considering personalised management options in the context of tumour size, patient wishes, and specific comorbidities. "Case of the Month" from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99mTc-sestamibi SPECT-CT to differentiate renal cell carcinoma from benign oncocytoma Abbreviations 99m Tc 99m technetium H&E haematoxylin and eosin ISRCTN International Standard Randomised Controlled Trial Number ROI region of interest RTB renal tumour biopsy SPECT single-photon emission CT Case Presentations Our first patient (P1) is a 69-year-old male with a 4-year history of a progressively enlarging left renal upper pole mass; contrast-enhanced CT demonstrated a 3.4-cm lesion in 2017, increasing in size on sequential cross-sectional imaging to 6.0 cm as of March 2021. [Extracted from the article]